Want to join the conversation?
$BMY 2Q15 Q&A: Fernandez of Leerink asked about features drove recommendations for utilization of CheckMate 12. Francis explained that the focus is really on maintaining efficacy in the combination. As far as efficacy is concerned, focused on durability of responses or overall survival or one year landmark survival and about therapeutic index.
$NFLX a monster move, going up. Expect making some money on Monday.
$AMD down more than 6% even after posting above consensus third quarter results.
$MCD stock rose more than 2% after it posted better than expected 3Q16 results, driven by global same-store sales growth. Meanwhile, earnings and revenue were lower than last year, hurt by refranchising efforts.